Leigh Ford

Leigh Ford

Auto-generated profile, based on publicly available information

Leigh Ford

Oral Drug Delivery Innovation, Chemical Division, Lonza Pharma Biotech & Nutrition, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2015 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
YSYasemin Sahbaz
Yasemin Sahbaz
HWHywel D. Williams
Hywel D. Williams
TNTri-Hung Nguyen
Tri-Hung Nguyen
JSJessica Saunders
Jessica Saunders
LFLeigh Ford
Leigh Ford
CPChristopher J. H. Porter
Christopher J. H. Porter

17 December 2013 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
HWHywel D. Williams
Hywel D. Williams
YSYasemin Sahbaz
Yasemin Sahbaz
LFLeigh Ford
Leigh Ford
TNTri-Hung Nguyen
Tri-Hung Nguyen
PSPeter J. Scammells
Peter J. Scammells
CPChristopher J. H. Porter
Christopher J. H. Porter
Custom-made ILs solubilized high quantities of the poorly water-soluble drugs, danazol and itraconazole, while a danazol self-emulsifying IL formulation gave rise to higher and more prolonged exposure than the crystalline drug and a lipid formulation, respectively.

10 October 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
YSYasemin Sahbaz
Yasemin Sahbaz
TNTri-Hung Nguyen
Tri-Hung Nguyen
LFLeigh Ford
Leigh Ford
CMClaire L. McEvoy
Claire L. McEvoy
HWHywel D. Williams
Hywel D. Williams
CPChristopher J. H. Porter
Christopher J. H. Porter

7 September 2010 in Green Chemistry
Verified
Journal Article
Closed access
PDF file
LFLeigh Ford
Leigh Ford
JHJitendra R. Harjani
Jitendra R. Harjani
FAFarzad Atefi
Farzad Atefi
MGMaria Teresa Garcia
Maria Teresa Garcia
RSRobert D. Singer
Robert D. Singer
PSPeter J. Scammells
Peter J. Scammells
A range of ionic liquids (ILs) containing a pyridinium cation were synthesised and their biodegradability was evaluated using the CO2 headspace test (ISO 14593). ILs bearing a 1-(2-hydroxyethyl) side chain were prepared from either pyridine or nicotinic acid derivatives. These ILs showed high levels of biodegradation under aerobic conditions and can be classified as ‘readily biodegradable’. In contrast, pyridinium ILs with methyl or ethyl ether side chains showed significantly lower levels of biodegradability in the same test. Biodegradation studies on a range of novel ILs with acetal and carbamate functionalities, as well as thiazolium-based salts, also showed low levels of mineralization.

1 January 2018 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
HWHywel D. Williams
Hywel D. Williams
LFLeigh Ford
Leigh Ford
SLShea Lim
Shea Lim
SHSifei Han
Sifei Han
JBJohn Baumann
John Baumann
CPChristopher J. H. Porter
Christopher J. H. Porter

30 October 2018 in Molecular Pharmaceutics
Verified
Journal Article
Open access
HWHywel D. Williams
Hywel D. Williams
LFLeigh Ford
Leigh Ford
SHSifei Han
Sifei Han
KTKristian J. Tangso
Kristian J. Tangso
SLShea Fern Lim
Shea Fern Lim
CPChristopher J. H. Porter
Christopher J. H. Porter
The absolute bioavailability of many small molecule kinase inhibitors (smKIs) is low. The reasons for low bioavailability are multifaceted and include constraints due to first pass metabolism and poor absorption. For smKIs where absorption limits oral bioavailability, low aqueous solubility and high lipophilicity, often in combination with high-dose requirements have been implicated in low and variable absorption, food-effects and absorption-related drug-drug interactions. The current study has evaluated whether preparation of smKIs as lipophilic salts/ionic liquids in combination with co-administration with lipid-based formulations is able to enhance absorption for examples of this compound class. Lipophilic (docusate) salt forms of erlotinib, gefitinib, ceritinib and cabozantinib (as example smKIs demonstrating low aqueous solubility and high lipophilicity) were prepared, and isolated as workable powder solids. In each case, the lipophilic salt exhibited high and significantly enhanced solubility in lipidic excipients (>100 mg/g) when compared to the free base or commercial salt form. Isolation as the lipophilic salt facilitated smKI loading in model lipid formulations at high concentration, increased in vitro solubilization at gastric and intestinal pH and in some cases increased oral absorption (~2-fold for cabozantinib formulations in rats). Application of a lipophilic salt approach can therefore facilitate the use of lipid-based formulations for examples of the smKI compound class where low solubility limits absorption and is a risk factor for increased variability due to food-effects.